ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1800

WWC1 Regulates Type I Interferon Production Through Modulation of cGAS-STING Signaling in Keratinocytes

Bin Xu, Laura Cencer, Benjamin Klein, Shannon Loftus, Lam Tsoi, Johann Gudjonsson and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI

Meeting: ACR Convergence 2024

Keywords: interferon, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: SLE – Etiology & Pathogenesis Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Our recent study uncovered a role for dysregulation of the Hippo signaling pathway in systemic lupus erythematosus (SLE) keratinocytes (KCs) driven by overexpression of WW domain containing protein 1 (WWC1). This overexpression results in chronic overactivation of Hippo signaling. SLE is also characterized by increased production of type I interferon (IFN) driven in part by activation of the cGAS-STING-TBK1-IRF3 pathway. This investigation sought to evaluate the interplay between WWC1-mediated HIPPO activation and type I IFN production via cGAS-STING signaling.

Methods: Human N/TERT keratinocytes that stably overexpress WWC1or GFP control were treated with the STING agonist 2’3’ cyclic GMP-AMP (cGAMP, 10 µg/mL)) or transfected with Z-DNA (625ng/well of 12 well plate) to activate cGAS-STING pathway. At 6 hours, phosphorylation of STING and TBK1 was assessed via Western blot, and total downstream gene expression was analyzed by RNA-seq and type I IFN and IFN-stimulated-genes (ISG) were evaluated by RT-qPCR. Similar experiments also were performed with or without IFNα priming.

Results: GFP-WWC1 in WWC1OE cell lines was localized to the perinuclear and cytoplasmic regions. As expected, WWC1OE upregulated the activity of LATS1/2 and increased phosphorylation of Yes-associated protein (YAP) at Ser397. Surprisingly, WWC1OE decreased the phosphorylation of TBK1 and STING in response to cGAMP induction and Z-DNA transfection, which led to a significant reduction of IFNB1, ISG15 and IRF7 expression. Furthermore, RNA-seq analysis confirmed a striking downregulation of type 1 interferon mediated signaling pathways when WWC1 was overexpressed. Upon further investigation, WWC1OE may also downregulate STING and YAP total protein content, suggesting that WWC1 may regulate the stability of cGAS-STING signaling components.

Conclusion: Our study reveals a novel role of WWC1 in regulation of type I interferon production through modulation of cGAS-STING signaling in keratinocytes. Further investigations will determine how the regulation of STING signaling by WWC1 can be utilized to understand and treat disease with high type I IFN expression.


Disclosures: B. Xu: None; L. Cencer: None; B. Klein: None; S. Loftus: None; L. Tsoi: Janssen, 5; J. Gudjonsson: AbbVie/Abbott, 12, support, Boehringer-Ingelheim, 12, support, Bristol-Myers Squibb(BMS), 12, support, Eli Lilly, 12, support, Janssen, 12, support, Novartis, 12, support; J. Kahlenberg: Amgen, 12, coauthor on publication, AstraZeneca, 2, Bristol-Myers Squibb(BMS), 2, 5, Eli Lilly, 2, Gilead, 2, GlaxoSmithKlein(GSK), 2, Janssen, 5.

To cite this abstract in AMA style:

Xu B, Cencer L, Klein B, Loftus S, Tsoi L, Gudjonsson J, Kahlenberg J. WWC1 Regulates Type I Interferon Production Through Modulation of cGAS-STING Signaling in Keratinocytes [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/wwc1-regulates-type-i-interferon-production-through-modulation-of-cgas-sting-signaling-in-keratinocytes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/wwc1-regulates-type-i-interferon-production-through-modulation-of-cgas-sting-signaling-in-keratinocytes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology